Non-pharmacological Effects in Switching Medication : The Nocebo Effect in Switching from Originator to Biosimilar Agent
Kristensen, Lars Erik (Lund University. Department of Internal Medicine, Rheumatology)
Alten, Rieke (Schlosspark Klinik, University Medicine Berlin. Department of Internal Medicine, Rheumatology)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Philipp, Sandra (Charité - Universitätsmedizin Berlin)
Kvien, Tore K. (Diakonhjemmet Hospital. Department of Rheumatology)
Mangues, Ma Antonia (Institut d'Investigació Biomèdica Sant Pau)
van den Hoogen, Frank (Radboud University Medical Centre. Department of Rheumatology)
Pavelka, Karel (Institute of Rheumatology)
Vulto, Arnold G. (KU Leuven. Department of Pharmaceutical and Pharmacological Sciences)
Universitat Autònoma de Barcelona

Date:	2018
Abstract:	The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals' understanding of biosimilars and utilising a managed switching programme.
Note:	Altres ajuts: This article was funded by Biogen International GmbH. Biogen International GmbH provided funding for medical writing support in the development of this paper, and reviewed and provided feedback on the paper to the authors.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; altres ; Versió publicada
Published in:	Biodrugs, Vol. 32 (september 2018) , p. 397-404, ISSN 1179-190X

DOI: 10.1007/s40259-018-0306-1
PMID: 30269270

8 p, 1.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles